Exchange: NASDAQ·Updated 07:52 PM EST
OMER logo

OMER Omeros Corp

$13.21
$0.80
(5.71%)
Today
Closed $13.21
$0.13
(0.98%)
After Hours
Reported EarningsNov 16
Mkt Cap$983.66M
Vol2.02M

About OMER

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
82

Extremely Bullish Sentiment

How do you feel about OMER?

hoffspeed
$OMER We shall see? The Ultimate "Tell" — The October 28 CEO Option Grant Why can we be so confident Q3 didn't miss consensus ($37.28M)? Look at the calendar: Q3 ended on September 30. By October 28, VP of Finance David Borges had already closed the Q3 accounting books and prepared the draft Form 10-Q for the Audit Committee. On that exact day (October 28), with the finalized Q3 sales number sitting in front of them, the Board of Directors awarded CEO Gregory Demopulos 500,000 performance options struck at $17.88 that forfeit 100% if the stock stays below $25.00. If Q3 revenue had come in below the $37.28M consensus, the Board would have known the stock was about to drop into the $14S or $15S on November 16—and any normal board would have waited until after the earnings drop to grant the CEO options at a lower $15.00 strike price. Pricing his strike at $17.88 on October 28 is a strong boardroom tell that Q3 cleared the bar.
32
LowCountry15
$OMER ARDS: The opportunity for OMER. Yartemlea's ARDS case rests on three signals. First, the Eli Lilly case: a 53-year-old Indiana man (Eli executive?), the first US patient treated with narsoplimab (Covid). Two weeks on a ventilator, failed remdesivir, tocilizumab, steroids, and convalescent plasma; after a four-week course he recovered fully and returned to work with no cognitive deficits. Second, the Bergamo six: every ventilated COVID ARDS patient at Papa Giovanni XXIII received full-dose narsoplimab within forty-eight hours of ventilation; all six survived, were discharged, and were clinically normal six months later with normal D-dimers. Third, I-SPY COVID: ninety-one randomized patients across twenty-seven US sites, hazard ratio zero point eight one, the largest mortality reduction of any drug arm, though roughly half the deaths happened before dosing or after early stoppage, so the treated population likely did better than the headline. No approved ARDS drug exists.
27
MagicPills
$OMER Re. ARDS: Despite decades of research and numerous failed clinical trials by major pharmaceutical and biotech companies, no consistently effective, disease-modifying drug treatment has emerged. If Omeros succeeds in demonstrating the clinical efficacy in ARDS, it could potentially address a large, underserved market and unlock a multibillion-dollar revenue opportunity.
1
21
LowCountry15
$OMER I think Greg’s price-based option grant from late October could be an important signal. Historically across biotech, similar grants have, in some instances, preceded significant near-term rerating catalysts, including accelerating commercial traction, drug approvals, and acquisitions. OMER shareholders should really be asking the question, why now?
27
kreftslag
Today , $OMER sits at $17 which results in a $1.3B market cap. Here's the setup: push this stock to ~$26 and Omeros crosses the $2B mcap line. Plenty of institutional funds have mandates with a minimum market-cap thresholds of $2B, so that's the point where we start showing up on their screeners. Earnings this week could be the spark. If the numbers land, the next buyers might not be retail. Be a smart retail this week
27
TRYII
$OMER You Newbies really need to chill with this "Buy Out" talk. Isn't going to happen anytime soon and it's not the story here. Stop being so short sighted, this story is much, much larger. Be well.
25
SteadyasSheGoes
$OMER HC Wainwright & Co. analyst Brandon Folkes reiterates Omeros(OMER) with a Buy and maintains $33 price target.
23
naturegirl669
$OMER - "Our regulatory efforts are currently focused outside the European Union as we work to obtain near-term approvals for YARTEMLEA in TA-TMA across a number of other countries whose regulatory bodies recognize and can build upon the drug's FDA approval. In parallel, we are working to make YARTEMLEA accessible internationally through fully reimbursed named patient programs in parts of Europe and other regions. While pursuing new markets for YARTEMLEA in TA-TMA, we are keenly focused on expanding its indications beyond TA-TMA. Too often, YARTEMLEA is narrowly thought of as a TA-TMA therapeutic. That understates YARTEMLEA's potential. Here's why. Endothelial injury is central to TA-TMA. Endothelial injury and other cellular damage directly activates the lectin pathway. So, YARTEMLEA, as a lectin pathway inhibitor, has the potential to treat a wide spectrum of disorders driven by endothelial injury."
20
hoffspeed
$OMER Give me $42+ million in sales. Tech transfer competion with Novo with maybe $20 million milestone payment. Update on ARDS. That will make me a happy 42nd Birthday surprise next week
24
Redsworld90
$OMER well so glad EC Monday and not today. FYI Doc already has a young wife and doesn’t need anything on the side. 😂 😆 😝
24
BigWayner
$OMER Should keep rising into earnings on Monday. Let’s hope the shorts start feeling some significant pain.
24
kreftslag
$OMER From zero commercial revenue in January to a $144M annualized net revenue run rate by September. That's an incredible launch trajectory in less than 9 months. With positive operating cash flow and adjusted net income already achieved, the market seems to be giving more weight to accounting noises than to the actual commercial progress.... So people now think paying of debt is a bad thing ? Always something new to hold us back it seems..
22
hmb
$OMER anyone else having dreams of $35 plus after earnings. Holding so strong through the turmoil the last couple weeks this is gonna launch if it beats
23
TRYII
$OMER I know what WE own. Bought more, again, again, again, again, again, again, again, again, etc.... Be well!
23
Arad288
$OMER I never thought I would pick up another 11,000 shares at this level ( which puts my average up to $5:10 per share now ) Let’s turn this ship around here
21
robertward
$OMER couldn’t help myself! Picked up another 8000 shares. Out of cash now but I’m sure this will pay off down the road. This time next year I honestly believe we’re gonna be north of $35 a share! It is no kidding time to buy 🙌
21
AndreasD
$OMER $OMER After selling my entire position at $20.50 and buying back right before the earnings call (terrible timing, my God!), I still see this sharp sell-off as a long-term opportunity. Greg has the flexibility to retire the remaining converts and potentially do further share buybacks once the $NVO cash comes in. I don’t expect significant upside over the next six months, but buying at these levels could turn out to be one of my better long-term investment decisions. Omeros is finally cash-flow positive, has a much healthier balance sheet, and Yartemlea keeps growing. Sure, the launch isn’t progressing as fast as the market hoped, but it’s exceeded my expectations so far. The market seems focused on short-term expectations while overlooking how much the company’s fundamentals have improved. Now let’s get the ARDS program moving and aim for what could become a multibillion-dollar drug approval. The next six months may require patience, but my long-term thesis remains intact.
16
MayorofMNKD
$OMER…. yes hate to be political here, but for those of you who voted Democrat, you got what you deserve today in the market let’s hope it doesn’t continue.
22
naturegirl669
$OMER - How many ARDS patients have been treated with yartemlea? "Yartemlea (narsoplimab) is not officially approved for Acute Respiratory Distress Syndrome (ARDS); its primary FDA approval is for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). However, across "published clinical trials and compassionate-use programs targeting COVID-19-associated ARDS", at least 106 patients have been explicitly documented as treated with the drug: • 91 patients were treated under the narsoplimab arm of the I-SPY COVID Trial across 27 sites in the United States. • 9 patients with severe ARDS requiring mechanical ventilation were treated in a follow-on ICU evaluation. • 6 patients with critically ill COVID-19-associated ARDS were treated in the initial small, multi-center compassionate-use study. Omeros Corporation has also noted plans to initiate additional dedicated clinical studies focusing on ARDS to formally expand the drug's indications."
21
rongside
$OMER Apparently an increase in sales and being cash flow positive alongside a potential expansion in Yartemlea treated indications is not enough. Perhaps in the next quarter we should be looking for a substantial fall in the share price, thus generating a GAAP non cash profit from the repricing of the embedded options. That is the essence of the accounting process used. Trading algorithms driven by headlines along with knowledgeable hedge funds use this nonsense to drive the price down. Christmas is early this year. Buy yourself a present ....... buy Omeros shares and have a Happy New Year.
19

Advertisement|Remove ads.